Could Prognostic Nutritional Index be a new criteria for active surveillance of prostate cancer?

Active surveillance Cáncer de próstata Prognostic nutritional index Prostate cancer Vigilancia activa Índice nutricional pronóstico

Journal

Actas urologicas espanolas
ISSN: 2173-5786
Titre abrégé: Actas Urol Esp (Engl Ed)
Pays: Spain
ID NLM: 101771154

Informations de publication

Date de publication:
11 2023
Historique:
received: 25 01 2023
revised: 10 03 2023
accepted: 13 03 2023
medline: 6 11 2023
pubmed: 23 4 2023
entrez: 22 04 2023
Statut: ppublish

Résumé

To evaluate the importance of the Prognotic Nutritional Index(PNI) value for patient selection of active surveillance(AS) in prostate cancer. Between September 2020 and June 2022, the data of 125-patients who underwent Robot-Assisted-Laparoscopic-Prostatectomy(RALP) were retrospectively analyzed. All patients were suitable for AS preoperatively. Using the pathological results of RALP, patients have been divided two groups. Patients who met the criteria for AS were defined as the first group, others were defined second. Demographic datas, PNI values and hematological parameters of the groups were compared. 38% (n:48) patients were found suitable for the group1, and 62%(n:77) were found suitable for the group 2. Upgrading and upstaging were found at 76 patients (61%) and 26(21%), respectively. There is no significant difference between groups on age, BMI, PSA, PSA-density, prostate volume, and PIRADS. PNI value was found higher at first group. The value of 49.45 was calculated by ROC analysis as the ideal PNI cut-off value for predicting upgrading and upstaging of prostate cancer (P < ,001). According to the both univariate and multivariate regression analysis, PNI was found a predictor for exclusion from AS (P < ,001). Upgrading and upstaging are detected at a higher rate in patients with low PNI values. The use of PNI value in the selection of patients to AS will increase the success rate of ideal patient selection.

Identifiants

pubmed: 37086847
pii: S2173-5786(23)00043-4
doi: 10.1016/j.acuroe.2023.04.003
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

573-580

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

E T Keskin (ET)

Servicio de Urología, Hospital Urbano de Basaksehir Cam y Sakura, Estambul, Turkey. Electronic address: emintaha90@hotmail.com.

H Özdemir (H)

Servicio de Urología, Hospital Urbano de Basaksehir Cam y Sakura, Estambul, Turkey.

R Uğur (R)

Servicio de Urología, Hospital Urbano de Basaksehir Cam y Sakura, Estambul, Turkey.

M Savun (M)

Servicio de Urología, Hospital Urbano de Basaksehir Cam y Sakura, Estambul, Turkey.

Y Çolakoğlu (Y)

Servicio de Urología, Hospital Urbano de Basaksehir Cam y Sakura, Estambul, Turkey.

A Şimşek (A)

Servicio de Urología, Hospital Urbano de Basaksehir Cam y Sakura, Estambul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH